Search results
Results from the WOW.Com Content Network
This registry based, multi-center, multi-country data provide provisional support for the use of ECMO for COVID-19 associated acute hypoxemic respiratory failure. Given that this is a complex technology that can be resource intense, guidelines exist for the use of ECMO during the COVID-19 pandemic. [85] [86] [87]
No participants had received a COVID‑19 vaccine or been previously infected with COVID‑19. [12] The main outcome measured in the trial was the proportion of people who were hospitalized due to COVID‑19 or died due to any cause during 28 days of follow-up. [12] EPIC-HR started in July 2021, and completed in December 2021. [51]
On 9 November 2012, Indian drugmaker Ranbaxy Laboratories Ltd. voluntarily recalled 10-, 20- and 40-mg doses of its generic version of atorvastatin in the United States. [ 134 ] [ 135 ] [ 136 ] The lots of atorvastatin, packaged in bottles of 90 and 500 tablets, were recalled due to possible contamination with very small glass particles similar ...
The most recent COVID-19 vaccine should offer protection against the XEC variant, Russo says. “The most recent version of the vaccine seems to be reasonably well-matched,” he says.
Bebtelovimab is a neutralizing human immunoglobulin G1 (IgG1) monoclonal antibody, isolated from a patient who has recovered from the Coronavirus disease 2019 (COVID-19), directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19.
The class is on the World Health Organization's List of Essential Medicines with simvastatin being the listed medicine. [10] In 2005, sales were estimated at US$18.7 billion in the United States. [11] The best-selling statin is atorvastatin, also known as Lipitor, which in 2003 became the best-selling pharmaceutical in history. [12]
The COVID-19 vaccines are widely credited for their role in reducing the severity and death caused by COVID-19. [ 128 ] [ 129 ] As of March 2023, more than 5.5 billion people had received one or more doses [ 130 ] (11.8 billion in total) in over 197 countries.
[10] [35] Participants were adults 18 and older with a pre-specified chronic medical condition or at increased risk of SARS-CoV-2 infection for other reasons who had not received a COVID‑19 vaccine. [10] The main outcome measured in the trial was the percentage of people who were hospitalized or died due to any cause during 29 days of follow ...